Analysts expect IntelGenx Technologies Corp. (CVE:IGX) to report $-0.05 EPS on April, 4.They anticipate $0.02 EPS change or 66.67 % from last quarter’s $-0.03 EPS. After having $-0.05 EPS previously, IntelGenx Technologies Corp.’s analysts see 0.00 % EPS growth. The stock decreased 2.13% or $0.02 during the last trading session, reaching $0.92. About 64,600 shares traded or 31.26% up from the average. IntelGenx Technologies Corp. (CVE:IGX) has 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. The company has market cap of $85.50 million. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. It currently has negative earnings. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer's disease.